Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Protocol EA2234: A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis - STOPGAP II

NCT07001748 is registered in ClinicalTrials.gov with ECOG-ACRIN Cancer Research Group as lead sponsor.

NCT NCT07001748
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07001748 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Protocol EA2234: A Randomized Phase II/III Trial of Intraperitoneal Paclitaxel Plus Systemic Treatment vs Systemic Treatment Alone in Gastric Carcinomatosis - STOPGAP II
Lead sponsor
ECOG-ACRIN Cancer Research Group
Phase
Phase 2/3
Overall status
Recruiting
Start date
October 24, 2025
Completion date
May 30, 2031
Enrollment
148 (estimated)
Sites
78

Conditions

As the registry lists them; a condition with its own page is linked.

gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, peritoneal carcinomatosis